Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 11Carcinoma, Hepatocellular 10Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 6Melanoma 4Endometrial Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Adenoid Cystic 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Clear Cell Carcinoma 1Non-squamous Non-small-cell Lung Cancer 1NSCLC 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

avelumab 7Nivolumab 5pembrolizumab 4Specimen Handling 3Ipilimumab 3Biopsy 3cemiplimab 2atezolizumab 2Radiotherapy 2Magnetic Resonance Spectroscopy 2tocilizumab 1talimogene laherparepvec 1prednylidene 1poly ICLC 1lutetium Lu 177 dotatate 1lenvatinib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1durvalumab 1deltacortene 1Tacrolimus 1Saline Solution 1Radiosurgery 1Radiation 1Prednisone 1MAPRE1 protein, human 1Lutetium-177 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Merkel Cell × lenvatinib × Clear all
NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
26 enrolled 9 charts
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡